NCT01505400Active, not recruiting
Integrated Molecular Profiling in Advanced Cancers Trial
Source: ClinicalTrials.gov · Last updated 14 Jul 2026
Brief summary (registry, in English)
Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient. Certain drugs are now being developed that target specific molecules in the body that are believed to be part of the disease. Biomarkers are specific characteristics of the cancer that may help provide prognostic information (i.e. how well patients will be regardless of the treatments given) or help predict sensitivity or resistance to a specific treatment. The study will collect archival tumor samples (previously collected biopsy or surgical tumor samples) to provide biomarker data about a patient's cancer, in order to help their physicians to identify which clinical trials of molecularly targeted therapies may be most appropriate for the patient in the future.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 3026 (actual)
- First submitted
- 4 Jan 2012
- Start date
- Feb 2012
- Primary completion date
- Jul 2027
- Lead sponsor
- University Health Network, Toronto
- Diseases
- Melanoma, Lung cancer, Colorectal cancer
- NCT number
- NCT01505400
What you commit to
- Study type: Observational
- Participants enrolled: 3026
- From Feb 2012 to the primary completion date, Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Patients with histological confirmation of advanced breast, non-small cell lung, colorectal, genitourinary, pancreatobiliary gastrointestinal, upper aerodigestive tract, gynecological, melanoma, unknown primary, and rare carcinomas who are candidates for systemic therapy, as well as patients who are phase I trial candidates.
- Patient must be ≥ 18 years old.
- Patient's ECOG performance status equal to 0 or 1.
- All patients must have signed and dated an informed consent form.
- All patients must have sufficient archived tumor tissue for molecular profiling.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Princess Margaret Hospital Coordinator of this site? Confirm its status | Toronto | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.